Group 1: Company Overview - Tianjin Jiuan Medical Electronics Co., Ltd. (referred to as "Jiuan Medical") held an investor online communication meeting on January 28, 2026, discussing product development, diabetes care "O+O" new model, AIoT diabetes home assistant project, sci-tech investment, and shareholder return planning [1] Group 2: IVD Product Progress - Jiuan Medical's IVD product, the iHealth four-in-one test kit, received FDA 510(k) pre-market notification in December 2025 and is now available for sale at CVS and on Amazon, priced at $29.99 for two tests and $49.99 for four tests [2] - The product expands the range of detectable viruses, meeting diverse respiratory virus screening needs in the U.S. market, enhancing core competitiveness [2] Group 3: Diabetes Care "O+O" New Model - The "O+O" model focuses on comprehensive diabetes management, with partnerships established in 424 hospitals across approximately 50 cities in China, managing over 366,000 patients [3] - The model has improved the glycated hemoglobin target rate from around 30% to 60%, with adverse event rates dropping below 5% and management rates increasing to 70% [3] - In the U.S., collaborations with about 74 clinics and 394 doctors are managing approximately 21,000 patients [3] Group 4: AIoT Diabetes Home Assistant - The AIoT diabetes home assistant project aims to develop an intelligent, personalized chronic disease management tool using advanced AI technology, with a complete AI module expected to launch in Q2 2026 [4] - The system is designed to enhance the efficiency of caregivers rather than replace them, utilizing a specialized AI model trained on health data from 366,000 diabetes patients [4] Group 5: Sci-Tech Investment - Since 2022, Jiuan Medical has committed over 4.3 billion yuan to various investment fields, including hard technology, healthcare, AI, and new materials, through partnerships with 27 venture capital funds [5][6] - The focus is on next-generation AI technologies and their applications, aiming for comprehensive coverage of the AI industry chain [6] Group 6: Shareholder Return Planning - Jiuan Medical has canceled 29,954,222 shares of treasury stock and plans to distribute cash dividends amounting to no less than 30% of cumulative net profits over the next three years [7] - The company aims to maintain market value and enhance stock price reflection of intrinsic value through strategic stock repurchases and improved business performance [7]